Knowledge Hubs
The latest news on genitourinary oncological disease states.
Prostate Cancer Knowledge Hubs
Advertisement
Renal Cell Carcinoma Knowledge Hubs
Advertisement
Urothelial Carcinoma Knowledge Hubs
Testicular, Penile, and Rare Malignancies Knowledge Hubs
Roundtable Discussions
Panel experts discuss PSMA-targeting agents currently being assessed, including PSMA-I&T-Lutetium-177.
Dr. Oliver Sartor and Dr. Rana McKay discuss some limitations (and advantages) of lutetium-177-PSMA.
Dr. Oliver Sartor weighs in on lutetium-177-PSMA as an effective therapy for prostate cancer.
The palliative benefits of lutetium-177 PSMA are discussed, including reduced symptom burden compared with standard of care.
Drs. George and Sprenkle discuss PSMA PET scans, including challenges and the potential of Lutetium-based PSMA treatments.
The panel discusses lutetium-177-PSMA for the treatment of advanced prostate cancer and reviews the VISION trial.
Advertisement
Advertisement
Editorial Advisory Board
Catherine H. Marshall, MD, MPHEditor-in-Chief | Assistant Professor of Oncology at the Johns Hopkins University School of Medicine
Jérémie Calais, MD, MScEditor | Director of the Theranostics and Clinical Research Programs at the University of California, Los Angeles
Akhil Abraham Saji, MDAssociate Editor | Urology Resident at New York Medical College/Westchester Medical Center
David Ambinder, MDAssociate Editor | Urology Resident at New York Medical College/Westchester Medical Center
